Contact Us  |  Site Map  |  Search  |  Client Login  
 
 
Boston Millennia Partners
   
   
  Boston Millennia Partners’ portfolio reflects Millennia’s commitment towards building enduring, large-scale businesses that have the potential to provide superior financial returns to our investors. Millennia’s portfolio is comprised of a diversified group of firms each positioned with the potential to become leaders in their respective market segments. We invite you to use the links below to learn more about each of those portfolio companies.  
     
 
  < Back   
 
 

    CombinatoRx, Incorporated
  650 Albany St.
  Boston, MA 02118

  Phone: 617-425-7000
  Fax: 617-425-7010
 
 
  CombinatoRx, Incorporated (NASDAQ: CRXX) is a biopharmaceutical company focused on developing new medicines built from synergistic combinations of approved drugs, designed to attack disease on multiple fronts. The company applies its proprietary combination drug discovery technology to identify new combination product candidates in a number of disease areas, including immuno-inflammatory disease, oncology, metabolic disease, neurodegenerative disease, and infectious disease. The company is currently developing a portfolio of six product candidates targeting multiple diseases which were discovered by applying its proprietary screening technology.

CombinatoRx is developing its combination drugs in response to the understanding that many diseases affect the body through multiple biological pathways. The activity of a therapeutic compound against one pathway can be insufficiently effective because biological systems often compensate by using a secondary pathway. The company believes that by targeting multiple pathways, its combination drug candidates may create synergistic therapeutic effects, which could result in improved treatments for many diseases.

CombinatoRx uses its combination high throughput screening, or cHTS™, technology, to systematically screen pair-wise combinations from its library of approximately 2,000 United States, European and Japanese approved drugs in cell-based assays corresponding to major diseases such as cancer, rheumatoid arthritis, asthma, psoriasis, hepatitis, neurodegenerative diseases and diabetes. Using these cell-based assays, the company’s cHTS technology screens the effects of millions of possible dose-specific combinations of existing drugs in each of our selected disease models.

CombinatoRx has discovered pairs of approved drugs which in preclinical studies exhibit a therapeutic effect against a model for a target disease when applied in combination, even though neither drug is indicated for such disease on its own. We have also discovered pairs of drugs where, our preclinical studies suggest the effectiveness or safety of one drug in its primary disease indication may be improved by combining it with another drug that, on its own, is not indicated for that disease.

 
Millennia Team  Dana Callow, Pat Fortune, Ph.D.
Visit the Website  http://www.combinatorx.com
Case Study  CombinatoRx (NasdaqGS:CRXX) has a proprietary platform to screen drug combinations in vitro and has thus far introduced six products into the clinic based on this platform. The company focuses on unique combinations of drugs that have already been approved by the FDA. With the well-publicized, safety-related failures of approved drugs after marketing had begun, we believe the company’s focus on combinations of existing drugs gives it a highly attractive drug development model. The company has created a current pipeline of drug candidates consisting of proprietary products with reduced safety risks in cancer, inflammation and other disease states, which have large addressable markets. The company went public in December 2005 to raise proceeds for development purposes and has raised additional funds in private placements. We believe that the company’s products are unusually attractive and the company has the potential to provide a high return on our investment.
Related News 

Cambridge, MA - May 27, 2009
CombinatoRx Reports Positive Phase 2 Trial Results for CRx-401

Cambridge, MA - May, 6, 2009
CombinatoRx Announces Oncology Collaboration with Novartis

Cambridge, MA - January 28, 2009
CombinatoRx Publishes Data on Selective Amplification of Synergistic Combination Drug Candidate

Cambridge, MA - December 9, 2008
CombinatoRx Presents New Data on B-Cell Malignancy Programs

Cambridge, MA - October 6, 2008
CombinatoRx Announces Top-Line Results from Phase 2b Study of Synavive(TM) (CRx-102) for Knee Osteoarthritis

Cambridge, MA - July 23, 2008
CombinatoRx Highlights Progress in Key Programs at 2008 R&D Day

Cambridge, MA - March 12, 2008
CombinatoRx Drug Candidate CRx-191 Demonstrates Positive Phase 2 Results in Psoriasis

Cambridge, MA - February 26, 2008
CombinatoRx Granted Broad Patent Covering TCA-Glucocorticoid Combinations

Cambridge, MA - January 24, 2008
CombinatoRx Provides Goals and Guidance for 2008

Cambridge and South Egremont, MA - November 8, 2007
CombinatoRx and Charley's Fund/Nash Avery Foundation Collaborate to Develop Novel Agents for Duchenne Muscular Dystrophy

Cambridge, MA - November 6, 2007
CombinatoRx Announces Initiation of Phase 2a Clinical Study of CRx-191 in Psoriasis

Cambridge, MA - October 25, 2007
CombinatoRx Publishes Clinical Study Results of CRx-102 in Hand Osteoarthritis

Cambridge, MA - October 22, 2007
CombinatoRx Receives Huntington's Disease Society Leadership Award

Cambridge, MA - October 11, 2007
CombinatoRx Announces Registered Direct Common Stock Offering of $35 Million

Cambridge, MA - September 26, 2007
CombinatoRx Announces Initiation of Phase 2b Clinical Study of CRx-102 in Knee Osteoarthritis

Cambridge, MA - August 14, 2007
CombinatoRx Announces Initiation of Phase 2a Proof-of-Concept Clinical Study with CRx-401 for Type 2 Diabetes

Cambridge, MA - June 4, 2007
CombinatoRx Adds Sally W. Crawford and W. James O'Shea to Its Board

Cambridge, MA - May 16, 2007
CombinatoRx Selected to Join NASDAQ Biotechnology Index

Cambridge, MA - April 17, 2007
CombinatoRx Announces the Identification of Synergistic Enhancers of TRAIL-Mediated Apoptosis

Cambridge, MA - March 26, 2007
CombinatoRx Provides Topline Results from Phase 2 RA Study with CRx-139 and Very Low Dose Prednisolone

Cambridge, MA - November 6, 2006
CombinatoRx Drug Candidate CRx-102 Demonstrates Positive Phase 2 Results in Rheumatoid Arthritis

Cambridge, MA - June 29, 2006
CombinatoRx to Be Included in Russell 3000 Index

Cambridge, MA - June 22, 2006
CombinatoRx Drug Candidate CRx-102 Demonstrates Statistically Significant Improvement in Pain and Other Clinical Measures

Cambridge, MA - June 5, 2006
CombinatoRx Appoints Michael Kauffman, MD, PhD to Its Board of Directors

Cambridge, MA & Bethesda, MD - June 1, 2006
CombinatoRx & Cystic Fibrosis Foundation Therapeutics Enter into a Collaboration to Develop Novel Therapeutics

Cambridge, MA - May 22, 2006
CombinatoRx Reports Second Positive Phase 2 Study with CRx-102

Cambridge, MA - April 24, 2006
CombinatoRx Appoints Lynn Baird, Ph.D., as Senior Vice President of Regulatory Affairs, QA/QC

Cambridge, MA & Singapore - April 21, 2006
CombinatoRx Receives Infectious Disease Research Grant Approval from Singapore's Economic Development Board

Cambridge, MA - April 18, 2006
CombinatoRx Reports Positive Results for CRx-170 in Phase 2 Proof-of-Concept Asthma Clinical Trial

Cambridge, MA - April 3, 2006
CombinatoRx Announces Discovery of Novel Synergistic Combination Leads for Glioblastoma

Boston, MA - March 23, 2006
CombinatoRx Announces $48.0 Million Private Placement

Boston, MA - January 30, 2006
CombinatoRx Drug Candidate CRx-102 Demonstrates Positive Phase 2 Study Results in Hand Osteoarthritis

Boston, MA - November 14, 2005
CombinatoRx Completes IPO

Boston, MA - November 9, 2005
CombinatoRx, Incorporated Announces Pricing of Its Initial Public Offering

BOSTON, MA – October 3, 2005
CombinatoRx and Angiotech Pharmaceuticals Sign Agreement

Boston, MA and Taipei, Taiwan - July 18, 2005
CombinatoRx Licenses CRx-026 Territory Rights to HenKan Pharmaceutical

Boston, MA - April 13, 2005
CombinatoRX Receives $4.4 Million Grant from the National Institute of Allergy and Infectious Diseases

Boston, MA and Burlingame, CA - Sept. 27, 2004
CombinatoRx and ABC2 Initiate Brain Cancer Collaboration

Boston, MA and New York, NY - VENTURE WIRE - September 13, 2004
CombinatoRx Signs Discovery Deal With Spinal Muscular Atrophy Foundation

Boston, MA – March 10, 2004
Boston Millennia Partners Leads $30 Million Venture Capital Investment in CombinatoRx, Incorporated

 
 

 

 
 
  | Our Firm      Our Team      Our Portfolio      Resources      News  
  © 2008 Boston Millennia Partners  All Rights Reserved